Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ENLV Enlivex Therapeutics Ltd
- Stocks
- Healthcare
- NASDAQ: ENLV
Price (delayed)
$0.93
Market cap
$22.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.66
Enterprise value
$1.63M
enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib
Highlights
Enlivex Therapeutics's EPS has soared by 53% YoY and by 10% from the previous quarter
Enlivex Therapeutics's net income has increased by 45% YoY and by 4.6% from the previous quarter
ENLV's equity is down by 23% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of ENLV
Market
Valuations
Earnings
Shares outstanding
23.85M
Market cap
$22.18M
Enterprise value
$1.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$15.27M
Net income
-$14.33M
EBIT
-$15.19M
EBITDA
-$14.74M
Free cash flow
-$12.92M
Per share
Balance sheet
Liquidity
EPS
-$0.66
EPS diluted
-$0.66
Free cash flow per share
-$0.54
Book value per share
$0.87
Revenue per share
$0
TBVPS
$1.01
Total assets
$24.04M
Total liabilities
$3.41M
Debt
$0
Equity
$20.63M
Working capital
$19.5M
Debt to equity
0
Current ratio
7.2
Quick ratio
6.54
Net debt/EBITDA
1.39
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.5%
Return on equity
-57.7%
Return on invested capital
-956.5%
Return on capital employed
-72.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENLV stock price
How has the Enlivex Therapeutics stock price performed over time
Intraday
-1.1%
1 week
-2.11%
1 month
-10.58%
1 year
-31.11%
YTD
-20.51%
QTD
-4.14%
Financial performance
How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.27M
Net income
-$14.33M
Gross margin
N/A
Net margin
N/A
Enlivex Therapeutics's net income has increased by 45% YoY and by 4.6% from the previous quarter
The company's operating income rose by 43% YoY and by 3.9% QoQ
Price vs fundamentals
How does ENLV's price correlate with its fundamentals
Growth
What is Enlivex Therapeutics's growth rate over time
Valuation
What is Enlivex Therapeutics stock price valuation
P/E
N/A
P/B
1.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enlivex Therapeutics's EPS has soared by 53% YoY and by 10% from the previous quarter
ENLV's P/B is 29% below its 5-year quarterly average of 1.5 and 2.7% below its last 4 quarters average of 1.1
ENLV's equity is down by 23% year-on-year and by 13% since the previous quarter
Efficiency
How efficient is Enlivex Therapeutics business performance
The ROIC has plunged by 51% from the previous quarter
Enlivex Therapeutics's ROE has increased by 22% YoY
Enlivex Therapeutics's ROA has increased by 18% YoY
Dividends
What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENLV.
Financial health
How did Enlivex Therapeutics financials performed over time
The total assets has declined by 23% year-on-year and by 13% since the previous quarter
The total liabilities has contracted by 19% YoY and by 17% from the previous quarter
ENLV's debt is 100% lower than its equity
ENLV's equity is down by 23% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.